Navigation Links
Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
Date:1/22/2008

candidate is intravenous iclaprim, a potent late-stage antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The US Food and Drug Administration has granted fast track status to intravenous iclaprim. In March 2007, Arpida completed patient enrolment in the second pivotal Phase III trial in complicated skin and skin structure infections. The top-line data of the second trial were reported in July 2007. The NDA-filing process is ongoing and expected to be completed by the end of February 2008.

In December 2007, Arpida announced the enrolment and dosing of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In January 2008, the US FDA granted authorisation to progress oral iclaprim into a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be highly effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal th
'/>"/>

SOURCE Arpida Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... FRANCISCO, Calif. , Nov. 24, 2014   Veracyte, ... Bonnie H. Anderson , president and chief executive officer, ... Jaffray 26 th Annual Healthcare Conference on Tuesday, December ... York . The live audio webcast and ... http://investor.veracyte.com . Please connect to the website at least ...
(Date:11/24/2014)... 2014 2014 Deep Research Report ... a professional and in-depth research report on the ... like its definition, classification, application, and industry chain ... covers the international market analysis, including China’s domestic ... US, Europe, Asia, China, Japan etc. regions) industry ...
(Date:11/24/2014)... 2014 Senior Vice President, General ... leadership skills, business acumen Elsevier , ... products and services, congratulates Diane Bartoli , Senior ... Workflow, Elsevier Clinical Solutions, for being recognized in the ... Awards issue of Profiles in Diversity Journal ...
(Date:11/22/2014)... During his lifetime Richard L. Sharp ... surround himself with great people and take risks to ... often marveled at his extraordinarily courageous attitude when taking ... -- even with his death impending—that’s how he continued ... would ultimately take his life. , Carrying on Sharp’s ...
Breaking Biology Technology:Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 2Adipic Dihydrazide Industry 2019 Research Forecasts on Worldwide, China Regions Now Available at ReportsnReports.com 3Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 2Sherry Sharp, Wife of CarMax Founder, Richard Sharp, Accepts Seat on Board of Cure Alzheimer’s Fund 3
... LOS ALTOS, Calif. , July 19 ... vitro fertilization (IVF) prognostic tools, announced today the publication ... the National Academy of Sciences ( PNAS ) by ... University .  The peer-reviewed paper details their development of the ...
... , July 19 Reportlinker.com announces that a new market research report is available in its catalogue: ... China In Vitro Diagnostics Market Outlook to 2016 , , ... , , China In ... Summary , , ...
... , July 19 Reportlinker.com announces that a new market research report is available in ... Stem Cells Market And Applications. 2009-2015 , ... http://www.reportlinker.com/p0239912/Stem-Cells-Market-And-Applications-2009-2015.html , , , ... , The ,Stem Cells Market and ...
Cached Biology Technology:Univfy and Stanford Scientists Develop the First Personalized Prognostic Test to Predict Live Birth Outcomes with In Vitro Fertilization 2Univfy and Stanford Scientists Develop the First Personalized Prognostic Test to Predict Live Birth Outcomes with In Vitro Fertilization 3Univfy and Stanford Scientists Develop the First Personalized Prognostic Test to Predict Live Birth Outcomes with In Vitro Fertilization 4Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 2Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 3Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 4Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 5Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 6Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 7Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 8Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 9Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 10Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 11Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 12Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 13Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 14Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 15Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 16Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 17Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 18Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 19Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 20Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 21Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 22Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 23Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 24Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 25Reportlinker Adds China In Vitro Diagnostics Market Outlook to 2016 26Reportlinker Adds Stem Cells Market And Applications. 2009-2015 2Reportlinker Adds Stem Cells Market And Applications. 2009-2015 3Reportlinker Adds Stem Cells Market And Applications. 2009-2015 4Reportlinker Adds Stem Cells Market And Applications. 2009-2015 5Reportlinker Adds Stem Cells Market And Applications. 2009-2015 6Reportlinker Adds Stem Cells Market And Applications. 2009-2015 7Reportlinker Adds Stem Cells Market And Applications. 2009-2015 8
(Date:11/3/2014)... -- Research and Markets has announced the addition ... and Companies" to their offering. This ... have already started to play an important role in the ... old fashioned bone marrow transplants. Role of cells in drug ... a part of medical practice. Stem cells are ...
(Date:11/3/2014)... low birth weight and preterm birth are linked to ... Findings published in the American College of Rheumatology (ACR) ... low birth weight and pre-term babies were not at ... adults. , According to the ACR, 27 million ... clinical OA. Symptoms of OA range from mild to ...
(Date:11/2/2014)... a flashlight up to our palms to see the ... Louis engineers are using a similar idea to track ... cancerous tissues and to develop potential treatments. , ... of Biomedical Engineering at the School of Engineering & ... allows researchers to better focus light in tissue, such ...
Breaking Biology News(10 mins):Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3Preterm, low birth-weight babies may need new hips in adulthood 2Improving imaging of cancerous tissues by reversing time 2
...  3-V Biosciences, Inc., announced today the appointment of Douglas ... brings more than 25 years of experience in the ... resulted in several marketed products and many more in ... entering the clinic in the next year, we are ...
... technical introduction to the SPring-8 Angstrom Compact free-electron Laser ... attention on the world,s second XFEL facility comes in ... the shortest wavelength in the world (0.63 Angstroms), an ... a very high peak output of 10 GW. SACLA ...
... at the largest-ever meeting of tropical biologists congratulated ... science, but warned that recent developments could jeopardize ... indigenous lands, and safeguarding ecosystems outside the Amazon ... 1200 tropical biologists and conservationists met in Bonito, ...
Cached Biology News:3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology 2Scientists warn Brazil's environmental leadership at risk 2Scientists warn Brazil's environmental leadership at risk 3
Mouse monoclonal antibody raised against a partial recombinant CRKRS. NCBI Entrez Gene ID = CRKRS...
... The BD PhosFlow Perm/Wash Buffer I can ... modified signaling proteins to permeabilize cells and ... cell wash buffer. Because saponin-mediated cell permeabilization ... to keep the cells in the presence ...
Mouse monoclonal antibody raised against a full length recombinant GPT. NCBI Entrez Gene ID = GPT...
Mouse monoclonal antibody raised against a partial recombinant TPR. NCBI Entrez Gene ID = TPR...
Biology Products: